| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Stoke Therapeutics, Inc. | Chief Patient Officer | Common Stock | 1,802 | $16,091 | $8.93 | 18 Jun 2025 | Direct |
| Provention Bio, Inc. | Chief Commercial Officer | Common Stock | 0 | $24.32 | 10 Feb 2023 | Direct | |
| Provention Bio, Inc. | Chief Commercial Officer | Option to Purchase Common Stock | 0 | 27 Apr 2023 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| STOK | Stoke Therapeutics, Inc. | 18 Jun 2025 | 0 | $0 | 3 | Chief Patient Officer | 23 Jun 2025, 16:16 |
| /report/000149315223013904-hoitt-jason-2023-04-27 | Provention Bio, Inc. | 27 Apr 2023 | 5 | $0 | 4 | Chief Commercial Officer | 27 Apr 2023, 18:00 |
| /report/000149315223005078-hoitt-jason-2023-02-10 | Provention Bio, Inc. | 10 Feb 2023 | 1 | -$45,005 | 4 | Chief Commercial Officer | 14 Feb 2023, 18:16 |
| /report/000149315223001208-hoitt-jason-2023-01-10 | Provention Bio, Inc. | 10 Jan 2023 | 1 | $0 | 4 | Chief Commercial Officer | 11 Jan 2023, 20:10 |
| /report/000149315222035096-hoitt-jason-2022-12-08 | Provention Bio, Inc. | 08 Dec 2022 | 2 | $0 | 4 | Chief Commercial Officer | 09 Dec 2022, 19:31 |
| /report/000149315222001752-hoitt-jason-2022-01-18 | Provention Bio, Inc. | 18 Jan 2022 | 1 | $0 | 4 | Chief Commercial Officer | 20 Jan 2022, 16:20 |
| /report/000149315221011579-hoitt-jason-2021-05-12 | Provention Bio, Inc. | 12 May 2021 | 1 | $0 | 4 | Chief Commercial Officer | 14 May 2021, 19:39 |